Pedro L Dago

Assistant Professor, Psychiatry and Behavioral Sciences

Phone+1 312 695 2608
Emailp-dago@northwestern.edu

Source: Scopus

Research activity per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Research Interests

Mood disorders, Psychopharmacology

Certifications and Licenses

Psychiatry

Training Experience

1991	Internship, Saint Luke's Hospital
1994	Residency, New York State Psychiatric Institute
1996	Fellowship, New York State Psychiatric Institute

Education/Academic qualification

Medicine, MD, University of Illinois at Chicago

… → 1990

Research interests

Anxiety Disorders
Cognitive Neuroscience
Depression
Mental Health
Mood Disorders
Neurology
Neuropsychology
Psychiatry

Fingerprint

Dive into the research topics where Pedro L Dago is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

6 Similar Profiles

5 Finished

Prot# BAP01346: Efficacy and Safety of Alitretinoin in the Treatment of Severe Chronic Hand Eczema Refractory to Topical Therapy
West, D. P., Dago, P. L. & Laumann, A. E.
Covance Periapproval Services, Inc., Basilea Pharmaceutica International Ltd.
5/26/09 → 5/26/12
Project: Research project
Biomarkers for Rapid Identification of Treatment Effectiveness in Major Depression (BRITE-MD)
Gilmer, W. S. & Dago, P. L.
Aspect Medical Systems, Inc.
3/1/06 → 1/10/08
Project: Research project
A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder
Gilmer, W. S. & Dago, P. L.
Cambridge Health Alliance, Janssen Pharmaceutica, Inc.
10/25/04 → 11/1/11
Project: Research project
Prot# 44-01101-000: A Randomized, Parallel-Group, Sham-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of The Neuronetics Model 2100 CRS Repetitive Transcranial Magnetic Stimulation (rTMS) System in Patients with Major Depr
Gilmer, W. S. & Dago, P. L.
Neuronetics, Inc.
8/17/04 → 3/12/10
Project: Research project
Double-Blind, Placebo-Controlled Trial Depakote-ER for Depressive and Anxiety Symptoms in Non-Refractory Bipolar Depression
Gilmer, W. S. & Dago, P. L.
Cambridge Health Alliance, Abbott Laboratories
6/25/04 → 12/31/08
Project: Research project

103 Citations
4 Article
1 Comment/debate
1 Letter
1 Review article

Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia
Keefe, R. S. E., Haig, G. M., Marder, S. R., Harvey, P. D., Dunayevich, E., Medalia, A., Davidson, M., Lombardo, I., Bowie, C. R., Buchanan, R. W., Bugarski-Kirola, D., Carpenter, W. T., Csernansky, J. T., Dago, P. L., Durand, D. M., Frese, F. J., Goff, D. C., Gold, J. M., Hooker, C. I., Kopelowicz, A. & 5 others, Loebel, A., McGurk, S. R., Opler, L. A., Pinkham, A. E. & Stern, R. G., Jan 1 2016, In: Schizophrenia bulletin. 42, 1, p. 19-33 15 p.
Research output: Contribution to journal › Article › peer-review
27 Scopus citations
Introduction: Treatment along the life cycle
Dago, P., Sep 1 2013, In: Psychiatric Times. 30, 9
Research output: Contribution to journal › Comment/debate › peer-review
Factors that impact choice of antidepressant treatment in medically complex patients.
Dago, P. L., Dec 2009, In: CNS spectrums. 14, 12 Suppl 12, p. 20-27 8 p.
Research output: Contribution to journal › Article › peer-review
1 Scopus citations
An association of intrusive, repetitive phrase with lomotrigine treatment in bipolar II disorder
Kemp, D. E., Gilmer, W. S., Fleck, J. & Dago, P. L., Feb 1 2007, In: CNS Spectrums. 12, 2, p. 106-111 6 p.
Research output: Contribution to journal › Review article › peer-review
15 Scopus citations
Aripiprazole augmentation for treatment-resistant bipolar depression: Sustained remission after 36 months [3]
Kemp, D. E., Dago, P. L., Straus, J. L., Fleck, J., Karaffa, M. & Gilmer, W. S., Jun 1 2007, In: Journal of Clinical Psychopharmacology. 27, 3, p. 304-305 2 p.
Research output: Contribution to journal › Letter › peer-review

13 Scopus citations